Severe downregulation of cardiac natriuretic peptide system in heart failure patients with systolic dysfunction as compared to without systolic dysfunction

2004 ◽  
Vol 10 (4) ◽  
pp. S46
Author(s):  
Keisuke Kawai ◽  
Seinosuke Kawashima ◽  
Eiichi Tajiri ◽  
Masuki Mori ◽  
Tomohiko Shirotani ◽  
...  
Keyword(s):  
Heart Failure ◽  
Natriuretic Peptide ◽  
Systolic Dysfunction ◽  
Heart Failure Patients ◽  
Peptide System ◽  
Natriuretic Peptide System

scholarly journals Possible Enzymatic Downregulation of the Natriuretic Peptide System in Patients with Reduced Systolic Function and Heart Failure: A Pilot Study

2018 ◽  
Vol 2018 ◽  
pp. 1-6 ◽  
Author(s):  
Syed S. Zaidi ◽  
Ryan D. Ward ◽  
Kodangudi Ramanathan ◽  
Xinhua Yu ◽  
Inna P. Gladysheva ◽  
...  
Keyword(s):  
Heart Failure ◽  
Pilot Study ◽  
Natriuretic Peptide ◽  
Systolic Function ◽  
Beta Blockers ◽  
Angiotensin Receptor Blockers ◽  
Systolic Dysfunction ◽  
Receptor Blockers ◽  
Peptide System ◽  
Natriuretic Peptide System

Background. In patients with reduced systolic function, the natriuretic peptide system affects heart failure (HF) progression, but the expression of key activating (corin) and degrading enzymes (neprilysin) is not well understood. Methods and Results. This pilot study (n=48) compared plasma levels of corin, neprilysin, ANP, BNP, and cGMP in control patients with normal ejection fractions (mean EF 63±3%) versus patients with systolic dysfunction, with (EF 24±8%) and without (EF 27±7%) decompensated HF (dHF), as defined by Framingham and BNP criteria. Mean ages, use of beta blockers, and ACE-inhibitors-angiotensin receptor blockers were similar between the groups. Corin levels were depressed in systolic dysfunction patients (797±346 pg/ml) versus controls (1188±549, p<0.02), but levels were not affected by dHF (p=0.77). In contrast, levels of neprilysin (p<0.01), cGMP (p<0.001), and ANP (p<0.001) were higher in systolic dysfunction patients than controls and were the highest in patients with dHF. Conclusions. Levels of neprilysin, ANP, BNP, and cGMP increased in patients with reduced systolic function and were the highest in dHF patients. Conversely, corin levels were low in patients with reduced EF with or without dHF. This pattern suggests possible enzymatic downregulation of natriuretic peptide activity in patients with reduced EF, which may have diagnostic and prognostic implications.

Attenuation of Compensation of Endogenous Cardiac Natriuretic Peptide System in Chronic Heart Failure

Circulation ◽  
1997 ◽  
Vol 96 (2) ◽  
pp. 509-516 ◽  
Author(s):  
Takayoshi Tsutamoto ◽  
Atsuyuki Wada ◽  
Keiko Maeda ◽  
Tomoko Hisanaga ◽  
Yukiharu Maeda ◽  
...  
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Natriuretic Peptide ◽  
Peptide System ◽  
Natriuretic Peptide System

scholarly journals Natriuretic Peptides and Analytical Barriers

2017 ◽  
Vol 63 (1) ◽  
pp. 50-58 ◽  
Author(s):  
Vlad C Vasile ◽  
Allan S Jaffe
Keyword(s):  
Heart Failure ◽  
Clinical Practice ◽  
Natriuretic Peptide ◽  
Natriuretic Peptides ◽  
Myocardial Function ◽  
Specific Assay ◽  
Peptide System ◽  
Cardiovascular Homeostasis ◽  
Natriuretic Peptide System

Abstract BACKGROUND The natriuretic peptide system is an endocrine, autocrine and paracrine system that plays an important role in the maintenance of cardiovascular homeostasis. Biomarkers based on these peptides are important diagnostic and prognostic tools for myocardial function. CONTENT Although natriuretic peptides were discovered more than 2 decades ago, their intricate and complex biology is associated with important questions not yet elucidated. The diversity of circulating forms of natriuretic peptides, the distinct expression of these forms in particular patients, and the heterogeneity of heart failure forms, along with specific assay-related and preanalytic issues, cause assays to be poorly harmonized. SUMMARY This review presents the relevant issues related to the biology of natriuretic peptides and differences between assays with immediate implications for clinical practice.

Natriuretic peptide system is not exhausted in severe heart failure

2009 ◽  
Vol 10 (1) ◽  
pp. 39-43 ◽  
Author(s):  
Patrícia Lourenço ◽  
Ana Azevedo ◽  
José Paulo Araújo ◽  
Paulo Bettencourt
Keyword(s):  
Heart Failure ◽  
Natriuretic Peptide ◽  
Severe Heart Failure ◽  
Peptide System ◽  
Natriuretic Peptide System

Implications of the natriuretic peptide system in the pathogenesis of heart failure: diagnostic and therapeutic importance

2004 ◽  
Vol 102 (3) ◽  
pp. 223-241 ◽  
Author(s):  
Zaid Abassi ◽  
Tony Karram ◽  
Samer Ellaham ◽  
Joseph Winaver ◽  
Aaron Hoffman
Keyword(s):  
Heart Failure ◽  
Natriuretic Peptide ◽  
Peptide System ◽  
Natriuretic Peptide System

Modulation of the natriuretic peptide system in heart failure: from bench to bedside?

2003 ◽  
Vol 105 (2) ◽  
pp. 141-160 ◽  
Author(s):  
Matthias SCHMITT ◽  
John R. COCKCROFT ◽  
Michael P. FRENNEAUX
Keyword(s):  
Heart Failure ◽  
Atrial Natriuretic Peptide ◽  
Natriuretic Peptide ◽  
Treatment Options ◽  
Scientific Success ◽  
Peptide System ◽  
Basic Concepts ◽  
Natriuretic Peptide System ◽  
Detailed Outline ◽  
Viable Treatment

Since the discovery of atrial natriuretic peptide, the unravelling of the natriuretic peptide system has been a story of scientific success. However, bridging the gap between bench and bedside has proved difficult, and as yet has not provided any major clinical progress. In this review we will first give a detailed outline of the key elements constituting the natriuretic peptide system. Secondly, we will briefly explain the underlying rationale, basic concepts and evidence behind currently pursued strategies to potentiate the natriuretic peptide system. Thirdly, we will highlight some of the problems that have so far hindered successful translation of these theoretically viable treatment options into tangible clinical progress.

Sign in / Sign up

Export Citation Format

Share Document